| Year | Sales (Million US Dollars) | Year-on-Year Variation (%) |
|---|---|---|
| 2024 | 1.3 | 0.0% |
| 2025 | 1.3 | 0.0% |
| 2026 | 1.3 | 0.0% |
| 2027 | 1.3 | 0.0% |
| 2028 | 1.3 | 0.0% |
The CAGR from 2024 to 2028 is 0.0%.
Future trends in the market for cardiac glycosides in Finland may be driven by advancements in medical technology, healthcare policies, and population demographics. Monitoring these factors will provide insight into potential shifts in demand and market opportunities.
